{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:06:02Z","timestamp":1768827962963,"version":"3.49.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Guidelines for the treatment of rheumatoid arthritis (RA) recommend the use of conventional synthetic disease modifying anti-rheumatic drugs (cs-DMARDs) at the onset of the disease and only in the case of therapeutic failure, the addition of a biological drug (b-DMARD) is suggested.<\/jats:p>\n            <jats:p>The study aimed to evaluate determinants for first-line biological treatment in patients with RA in clinical practice.<\/jats:p>\n            <jats:p>A cohort of patients with RA, resident in Lazio, a central Italian Region, where Rome is located, and with at least one disease modifying anti-rheumatic drugs (DMARD) prescription between 2010 and 2016 was selected using health information systems linkable with each other by an individual unique anonymous identifier. In particular RA cohort was defined retrieving all patients with at least a RA disease code in regional data claims (hospital discharge, exemption code, emergency department access, or therapeutic plan). Only new users were included and the first-line treatment was identified: cs-DMARD or b-DMARD.<\/jats:p>\n            <jats:p>Descriptive analysis according to type of DMARD treatment was performed. Through multivariate logistic regression models (odds ratio [OR]; confidence interval [CI95%]) determinants of therapy such as age, comorbidity, and comedication were investigated.<\/jats:p>\n            <jats:p>Finally, switching during the first year of treatment from cs-DAMARDs to b-DMARDs was analyzed.<\/jats:p>\n            <jats:p>DMARD-new users with RA were 5641; 7.1% of them with b-DMARD as first-line treatment. Considering the year of dispensing, this percentage ranged from 4.9% (2011) to 8.2% (2015). Among cs-DMARD the most prescribed active agent was methotrexate (59.3%), while among b-DMARD it was etarnecept (37.0%), followed by adalimumab (21.2%). The average age of the cohort was 54\u200ayears with 77% of women. Determinants of first-line b-DMARD use were: age (OR<jats:sub>&lt;30vs&gt;65<\/jats:sub>\u200a=\u200a3.7; 2.6\u20135.2, OR<jats:sub>[30\u201345)vs&gt;65<\/jats:sub>\u200a=\u200a1.7; 1.2\u20132.4, OR<jats:sub>[45\u201355)vs&gt;65<\/jats:sub>\u200a=\u200a1.6; 1.1\u20132.4, OR<jats:sub>[55\u201365)vs&gt;65<\/jats:sub>\u200a=\u200a1.2; 0.8\u20131.7), cancers (OR\u200a=\u200a2.3; 1.3\u20134.2), cardio-cerebrovascular disease (OR\u200a=\u200a1.4; 1.0\u20131.9), use of non-steroidal anti-inflammatory drugs (NSAIDs) (OR\u200a=\u200a0.6; 0.4\u20130.7) and corticosteroids (OR\u200a=\u200a0.6; 0.5\u20130.7) in the 6 months preceding diagnosis.<\/jats:p>\n            <jats:p>In the first year of treatment, we observed a percentage of switch from cs-DMARDs to b-DMARDs of 7.9%.<\/jats:p>\n            <jats:p>In clinical practice, about 7% of patients with RA are prescribed with a b-DMARD as first-line treatment. This therapeutic option, even if not supported by guide lines, is mostly link to younger age and clinical profile of the patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000025943","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T19:58:40Z","timestamp":1620763120000},"page":"e25943","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Determinants of first-line biological treatment in patients with rheumatoid arthritis"],"prefix":"10.1097","volume":"100","author":[{"given":"Laura","family":"Angelici","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Addis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nera","family":"Agabiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Kirchmayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Davoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8286-443X","authenticated-orcid":false,"given":"Valeria","family":"Belleudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","article-title":"The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study","volume":"73","author":"Cross","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00296-014-2974-6","article-title":"Prevalence and incidence of rheumatoid arthritis in Italy","volume":"34","author":"Rossin","year":"2014","journal-title":"Rheumatol Int"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12016-018-8672-5","article-title":"Sex and management of rheumatoid arthritis","volume":"56","author":"Favalli","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40744-017-0073-3","article-title":"Treatment with biologicals in rheumatoid arthritis: an overview","volume":"4","author":"Rein","year":"2017","journal-title":"Rheumatol Ther"},{"key":"R5-20250504","first-page":"1245","article-title":"Diagnosis and management of rheumatoid arthritis","volume":"84","author":"Wasserman","year":"2011","journal-title":"Am Fam Physician"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"51","DOI":"10.18773\/austprescr.2017.012","article-title":"Managing the drug treatment of rheumatoid arthritis","volume":"40","author":"Wilsdon","year":"2017","journal-title":"Aust Prescr"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"76","author":"Nam","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1759720X16665330","article-title":"Combination therapy with biologic agents in rheumatic diseases: current and future prospects","volume":"8","author":"Inui","year":"2016","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R11-20250504","first-page":"09","article-title":"The efficacy and safety of mainstream medications for patients with cDMARD-Na\u00efve rheumatoid arthritis: a network meta-analysis","volume":"21","author":"Cai","year":"2018","journal-title":"Front Pharmacol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"e0194130","DOI":"10.1371\/journal.pone.0194130","article-title":"Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis - The ANSWER cohort study","volume":"13","author":"Ebina","year":"2018","journal-title":"PLoS One"},{"key":"R13-20250504","first-page":"417","article-title":"Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis","volume":"56","author":"Tarp","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40264-018-0732-5","article-title":"The role of European Healthcare Databases for post-marketing drug effectiveness, safety and value evaluation: where does Italy stand?","volume":"42","author":"Trifir\u00f2","year":"2019","journal-title":"Drug Saf"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"e006029","DOI":"10.1136\/bmjopen-2014-006029","article-title":"A validation study of a new classification algorithm to identify rheumatoid arthritis using administrative health databases: case-control and cohort diagnostic accuracy studies. Results from the RECord linkage On Rheumatic Diseases study of the Italian Society for Rheumatology","volume":"5","author":"Carrara","year":"2015","journal-title":"BMJ Open"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1002\/pds.3334","article-title":"The incident user design in comparative effectiveness research","volume":"22","author":"Johnson","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R17-20250504","first-page":"03","article-title":"A systematic review of guidelines for managing rheumatoid arthritis","volume":"22","author":"Mian","year":"2019","journal-title":"BMC Rheumatol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e1917053","DOI":"10.1001\/jamanetworkopen.2019.17053","article-title":"Association of patient, prescriber, and region with the initiation of first prescription of biologic disease-modifying antirheumatic drug among older patients with rheumatoid arthritis and identical health insurance coverage","volume":"2","author":"Tatangelo","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/acr.22640","article-title":"Physician preferences and variations in prescription of biologic drugs for rheumatoid arthritis: a register-based study of 4,010 patients in Sweden","volume":"67","author":"Kalkan","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R20-20250504","first-page":"12","article-title":"Early start and stop of biologics: has the time come?","volume":"6","author":"van Vollenhoven","year":"2014","journal-title":"BMC Med"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1136\/annrheumdis-2016-210246","article-title":"\u201cClinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomized trial.\u201d","volume":"76","author":"Atsumi","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R22-20250504","first-page":"10","article-title":"Adverse events in patients with rheumatoid arthritis and psoriatic arthritis receiving long-term biological agents in a real-life setting","volume":"11","author":"Barros","year":"2019","journal-title":"Front Pharmacol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/acr.23875","article-title":"Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"72","author":"Singh","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/rheumatology\/kep129","article-title":"Laan RFJM Missed opportunities in the treatment of elderly patients with rheumatoid arthritis","volume":"48","author":"Radovits","year":"2009","journal-title":"Rheumatology"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40744-015-0021-z","article-title":"Biologics prescribing for rheumatoid arthritis in older patients: a single-center retrospective cross-sectional study","volume":"2","author":"Morsley","year":"2015","journal-title":"Rheumatol Ther"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s00296-018-4161-7","article-title":"Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data","volume":"38","author":"Steffen","year":"2018","journal-title":"Rheumatol Int"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s11606-019-05230-0","article-title":"Comparative effectiveness of combining MTX with biologic drug therapy versus either MTX or biologics alone for early rheumatoid arthritis in adults: a systematic review and network meta-analysis","volume":"34","author":"Donahue","year":"2019","journal-title":"J Gen Intern Med"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/acr.23470","article-title":"Early rheumatoid arthritis presentation, treatment, and outcomes in aboriginal patients in Canada: A Canadian Early Arthritis Cohort Study Analysis","volume":"70","author":"Nagaraj","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:43:03Z","timestamp":1746337383000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025943"}},"subtitle":["Results from an observational study"],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":28,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025943","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]},"assertion":[{"value":"2020-06-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}